Amrita Therapeutics Ltd.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Amrita Therapeutics Ltd. - overview
Established
2008
Location
Ahmedabad, Gujarat, India
Primary Industry
Biotechnology
About
Amrita Therapeutics Ltd. is a biotechnology firm engaged in the development and manufacturing of high-quality antibodies, biological products, and diagnostic tools for laboratories and healthcare providers. Founded in 2008 in Ahmedabad, India, Amrita Therapeutics specializes in developing antibody-based therapies and diagnostic solutions. The firm completed a financing round in July 2008, securing INR 20 million from GVFL.
CEO Pavel Tarlov leads the company, which has been focused on advancing its product offerings without any known pivots or changes in direction. Amrita Therapeutics offers a variety of products, including monoclonal, polyclonal, recombinant, and custom antibodies, all rigorously tested for applications in ELISA, Western Blot, Flow Cytometry, Immunohistochemistry, and Immunofluorescence. The company also develops biological therapeutics such as immunotherapies and cytokines, alongside diagnostic tools like ELISA kits and rapid test kits for detecting infections and autoimmune diseases. Its clientele comprises university and hospital laboratories, biotech firms, and public health agencies across Europe, North America, and parts of Asia.
In the most recent financial year, 2018, Amrita Therapeutics reported zero revenue and an EBITDA of INR -3,134. 2 mn, indicating a loss. Amrita Therapeutics is actively designing new diagnostic products and anticipates launching these offerings by the end of 2023. The company aims to expand its market reach into Europe and North America through strategic partnerships and collaborations, supported by the INR 20 million financing from GVFL completed in July 2008.
These funds are earmarked for enhancing product development and increasing market penetration.
Current Investors
GVFL
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Medical Devices & Equipment, Pharmaceutical Research & Development
Website
www.amritatherapeutics.com
Verticals
HealthTech
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only
Amrita Therapeutics Ltd. - financials
| Fiscal Year Ended | Mar 31, 2009 | Mar 31, 2010 | Mar 31, 2011 | Mar 31, 2012 | Mar 31, 2013 | Mar 31, 2014 | Mar 31, 2015 | Mar 31, 2016 | Mar 31, 2017 | Mar 31, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | - | - | 3,140,922 | - | - | 2,879,700 | - | - | - | - |
| % Revenue Growth (YoY) | - | - | - | (100.0%) | - | - | (100.0%) | - | - | - |
| EBITDA (USD) | - | - | 72,453 | 102,963 | 102,963 | 102,963 | 481,655 | - | - | - |
| Operating Income (USD) | - | - | - | - | - | - | - | - | - | - |
| Operating Margin | - | - | - | - | - | - | - | - | - | - |
| % EBITDA Margin | - | - | 2.3% | - | - | 3.6% | - | - | - | - |
| NET Income (USD) | - | - | - | - | - | - | - | - | - | - |
| % Net Margin | - | - | - | - | - | - | - | - | - | - |
Amrita Therapeutics Ltd. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.